Overview

• Novo Nordisk's Ozempic and Wegovy see soaring sales in China, driven by their weight-loss effects.
• Chinese firms are developing numerous generic versions of these drugs, anticipating the expiration of Novo's patent in 2026.
• Counterfeit weight-loss drugs are proliferating online, prompting increased regulatory scrutiny.
• High prices on e-commerce platforms reflect the intense demand for effective weight-loss solutions.
• Future market leadership hinges on regulatory outcomes and the ability to scale production.